Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.46 |
| ▸ | CNR1 | P21554 | 4/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18213630 | 0.84 | CNR2 (0.64) | CNR2CNR1LDHAPPARGTRPM8 | |
| SCHEMBL16348132 | 0.79 | CNR1 (0.63) | CNR2CNR1LDHATRPM8 | |
| SCHEMBL14455992 | 0.79 | CNR1 (0.63) | CNR2CNR1LDHATRPM8 | |
| SCHEMBL31545911 | 0.79 | CNR1 (0.63) | CNR2CNR1LDHATRPM8 | |
| SCHEMBL13214093 | 0.79 | CNR1 (0.63) | CNR2CNR1LDHATRPM8 | |
| SCHEMBL25098127 | 0.79 | CNR1 (0.63) | CNR2CNR1LDHATRPM8 | |
| SCHEMBL13214090 | 0.79 | CNR1 (0.63) | CNR2CNR1LDHATRPM8 | |
| SCHEMBL3056413 | 0.79 | CNR1 (0.63) | CNR2CNR1LDHATRPM8 | |
| SCHEMBL28726728 | 0.79 | CNR1 (0.63) | CNR2CNR1LDHATRPM8 | |
| SCHEMBL28726746 | 0.79 | CNR1 (0.63) | CNR2CNR1LDHATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| EP-3291807-B1 | HYDROGENATION OF CANNABIS OIL | SCIALDONE MARK ANDREW (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190030102-A1 | HYDROGENATION OF CANNABIS OIL | RESEARCH GROW LABS | 2019-01-31 | — | — | US | disclosed |
| US-20170266245-A1 | HYDROGENATION OF CANNABIS OIL | RESEARCH GROW LABS | 2017-09-21 | — | — | US | disclosed |
| US-20170266245-A1 | HYDROGENATION OF CANNABIS OIL | RESEARCH GROW LABS | 2017-09-21 | — | — | US | disclosed |
| US-9694040-B2 | Hydrogenation of cannabis oil | RESEARCH GROW LABS | 2017-07-04 | — | — | US | disclosed |
| US-9694040-B2 | Hydrogenation of cannabis oil | RESEARCH GROW LABS | 2017-07-04 | — | — | US | disclosed |
| US-20160324909-A1 | HYDROGENATION OF CANNABIS OIL | RESEARCH GROW LABS | 2016-11-10 | — | — | US | disclosed |
| US-20160324909-A1 | HYDROGENATION OF CANNABIS OIL | RESEARCH GROW LABS | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190030102-A1 | HYDROGENATION OF CANNABIS OIL | CNR2, CNR1, HHAT | CNR2 1/4885CNR1 2/4885LDHA 3657/4885 |
| US-20160324909-A1 | HYDROGENATION OF CANNABIS OIL | CNR2, CNR1, HHAT | CNR2 1/4885CNR1 2/4885LDHA 3657/4885 |
| US-20170266245-A1 | HYDROGENATION OF CANNABIS OIL | CNR2, CNR1, HHAT | CNR2 1/4885CNR1 2/4885LDHA 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.